Publicaties

2022

Prophylactic medication for the prevention of endoscopic recurrence in Crohn’s disease: a prospective study based on clinical risk stratification

Jeanine H C Arkenbosch, Evelien M J Beelen, Gerard Dijkstra, Mariëlle Romberg-Camps, Marjolijn Duijvestein, Frank Hoentjen, Sander van der Marel, P W Jeroen Maljaars, Sita Jansen, Nanne K H de Boer, Rachel L West, Carmen S Horjus, Laurents P S Stassen, Fiona D M van Schaik, Oddeke van Ruler, Bindia J H Jharap, Marijn Visschedijk, Alfred Janssen, Nicole S Erler, Michail Doukas, Ariadne H A G Ooms, Gursah Kats-Ugurlu, C Janneke van der Woude, Annemarie C de Vries, Dutch Initiative on Crohn’s and Colitis (ICC)

J Crohns Colitis. 2022 Sep 12;jjac128. doi: 10.1093/ecco-jcc/jjac128. Online ahead of print.

Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn’s disease: a cross-sectional study

M M van de Meeberg, M L Seinen, H H Fidder, M Lin, B Oldenburg, N K de Boer, G Bouma, R de Jonge, M Bulatović Ćalasan, Dutch Initiative on Crohn and Colitis (ICC)

BMC Gastroenterol. 2022 Jul 30;22(1):365. doi: 10.1186/s12876-022-02439-y.

Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases

Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Amber Sales, Amit Levran, Fiona van Schaik, Jeroen Maljaars, Krisztina Gecse, Cyriel Ponsioen, Joep Grootjans, Jurij Hanzel, Greetje Tack, Jeroen Jansen, Frank Hoentjen, Nanne de Boer, Sander van der Marel, Gerard Dijkstra, Bas Oldenburg, Mark Löwenberg, Andrea van der Meulen, Geert D Haens, IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis

Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. doi: 10.1111/apt.17153. Epub 2022 Jul 23.

Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

Tessa Straatmijer, Vince BC Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A van Bodegraven, Alexander Bodelier, Nanne KH de Boer, Gerard Dijkstra, Noortje Festen, Carmen Horjus, Jeroen M Jansen, Bindia Jharap, Wout Mares, Fiona DM van Schaik, Cyriel Ponsioen, Tessa Romkens, Nidhi Srivastava, Michael MPJA van der Voorn, Rachel West, Janneke van der Woude, Marije DJ Wolvers, Marieke Pierik, Andrea E van der Meulen-de Jong, Marjolijn Duijvestein, Initiative on Crohn and Colitis (ICC)

Clin Gastroenterol Hepatol. 2022 May 26;S1542-3565(22)00510-9. doi: 10.1016/j.cgh.2022.04.038. Online ahead of print.

The launch of an online national multidisciplinary expert panel for inflammatory bowel disease

Nanne K de Boer, Florine L van Lookeren, Greetje J Tack, Dutch Initiative on Crohn and Colitis (ICC)
J Crohns Colitis. 2022 Jan 6;jjac002. doi: 10.1093/ecco-jcc/jjac002. Online ahead of print


2021

Ustekinumab for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.

Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G, van Dop WA, Haans JJL, Jansen JM, Maljaars PWJ, van der Marel S, Oldenburg B, Ponsioen CY, Visschedijk MC, de Vries AC, West RL, van der Woude CJ, Pierik M, Duijvestein M, van der Meulen-de Jong AE.J Crohns Colitis. 2021 Apr 28:jjab081. doi: 10.1093/ecco-jcc/jjab081. Online ahead of print.PMID: 33909062

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.

Kanis SL, Modderman S, Escher JC, Erler N, Beukers R, de Boer N, Bodelier A, Depla ACTM, Dijkstra G, van Dijk ARM, Gilissen L, Hoentjen F, Jansen JM, Kuyvenhoven J, Mahmmod N, Mallant-Hent RC, van der Meulen-de Jong AE, Noruzi A, Oldenburg B, Oostenbrug LE, Ter Borg PCJ, Pierik M, Romberg-Camps M, Thijs W, West R, de Lima A, van der Woude CJ; Initiative on Crohns and Colitis (ICC).Gut. 2021 Jul;70(7):1266-1274. doi: 10.1136/gutjnl-2019-319129. Epub 2020 Oct 12.PMID: 33046558

Healthy Cotwins Share Gut Microbiome Signatures With Their Inflammatory Bowel Disease Twins and Unrelated Patients.

Brand EC, Klaassen MAY, Gacesa R, Vich Vila A, Ghosh H, de Zoete MR, Boomsma DI, Hoentjen F, Horjus Talabur Horje CS, van de Meeberg PC, Willemsen G, Fu J, Wijmenga C, van Wijk F, Zhernakova A, Oldenburg B, Weersma RK; Dutch TWIN-IBD consortium and the Dutch Initiative on Crohn and Colitis.Gastroenterology. 2021 May;160(6):1970-1985. doi: 10.1053/j.gastro.2021.01.030. Epub 2021 Jan 19.PMID: 33476671

Decreasing Trends in Intestinal Resection and Re-Resection in Crohn’s Disease: A Nationwide Cohort Study.

Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC; Dutch Initiative on Crohn's and Colitis (ICC).Ann Surg. 2021 Mar 1;273(3):557-563. doi: 10.1097/SLA.0000000000003395.PMID: 31188225


2020

Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab.

Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, Löwenberg M, Srivastava N, Bodelier AGL, West RL, Jansen JM, de Vries AC, Haans JJL, de Jong DJ, Pierik MJ, Hoentjen F.Clin Pharmacol Ther. 2020 May;107(5):1189-1199. doi: 10.1002/cpt.1712. Epub 2019 Dec 11.PMID: 31677154 

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment.

Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, LöwenbergM, de Boer NK, Oldenburg B, Srivastava N, Jansen JM, Bodelier AGL, West RL, de Vries AC, Haans JJL, de Jong D, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC).Aliment Pharmacol Ther. 2020 Jul;52(1):123-134. doi: 10.1111/apt.15745. Epub 2020 May 22.PMID: 32441396

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.

Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC).Aliment Pharmacol Ther. 2020 May;51(9):880-888. doi: 10.1111/apt.15689. Epub 2020 Apr 1.PMID: 32237087

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.

Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, Löwenberg M, Dijkstra G, Oldenburg B, de Boer NKH, van der Marel S, Bodelier AGL, Jansen JM, Haans JJL, Theeuwen R, de Jong D, Pierik MJ, Hoentjen F.J Crohns Colitis. 2020 Jan 1;14(1):33-45. doi: 10.1093/ecco-jcc/jjz119.PMID: 3121915


2019

Off-label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis.

Simsek M, Lissenberg-Witte BI, van Riswijk MLM, Verschuren S, Hoentjen F, Oldenburg B, Ponsioen CY, van der Woude CJ, van der Meulen AE, Pierik M, Dijkstra G, de Boer NKH; Parelsnoer Institute (PSI), the Dutch Initiative on Crohn's and Colitis (ICC).Aliment Pharmacol Ther. 2019 May;49(10):1293-1300. doi: 10.1111/apt.15229. Epub 2019 Mar 25.PMID: 30908719

Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.

Simsek M, Meijer B, Ramsoekh D, Bouma G, van der Wouden EJ, den Hartog B, de Vries AC, Hoentjen F, Dijkstra G, de Boer SY, Jansen JM, van der Meulen AE, Beukers R, Brink MA, Steinhauser T, Oldenburg B, Gilissen LP, Naber TH, Verhagen MA, de Boer NKH, Mulder CJJ; Dutch Initiative on Crohn and Colitis (ICC).Clin Gastroenterol Hepatol. 2019 Feb;17(3):568-570. doi: 10.1016/j.cgh.2018.05.009. Epub 2018 Jun 1.PMID: 29775790


2018

Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study.

Nissen LHC, Derikx LAAP, Jacobs AME, van Herpen CM, Kievit W, Verhoeven R, van den Broek E, Bekers E, van den Heuvel T, Pierik M, Rahamat-Langendoen J, Takes RP, Melchers WJG, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis (ICC); Dutch Head and Neck Society, PALGA group; IBD/HNC group.Inflamm Bowel Dis. 2018 Aug 16;24(9):2015-2026. doi: 10.1093/ibd/izy096.PMID: 30759216

Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness.

Meijer B, Mulder CJJ, Bouma G, Ponsioen CY, van der Woude CJ, van der Meulen AE, Wintjens DSJ, Dijkstra G, Hoentjen F, Oldenburg B, van Bodegraven AA, de Boer NKH; Dutch Initiative on Crohn and Colitis (ICC) and Parelsnoer Institute. Inflamm Bowel Dis. 2018 Jun 8;24(7):1558-1565. doi: 10.1093/ibd/izy047.PMID: 29668998


2017

Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.

Severs M, Mangen MJ, van der Valk ME, Fidder HH, Dijkstra G, van der Have M, van Bodegraven AA, de Jong DJ, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, Ponsioen CY, Vermeijden JR, van der Meulen-de Jong AE, Pierik M, Siersema PD, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis. J Crohns Colitis. 2017 Mar 1; 11(3):342-252

Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.

Severs M, Mangen MJ, Fidder HH, van der Valk ME, van der Have M, van Bodegraven AA,m Clemens CHM, Dijkstra G, Jansen JM, de Jong DJ, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong, AE, Pierik M, Ponsioen CY, Romberg-Camps MJL, Siersema PD, Jharap B, van der Woude JC, Zuithoff NPA, Oldenburg B. Inflamm Bowel Dis. 2017 Sep;23(9):1568-1576

The impact of ethnicity and country of birth on inflammatory bowel disease phenotype, a prospective cohort study.

Spekhorst LM, Severs M, de Boer KHN, et al.; on behalf of the Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC). J Crohns Colitis 2017

Cohort profile: Design and first results of the Dutch IBD Biobank: a porspective, nationwide biobank of patients with inflammatory bowel disease.

Spekhorst LM, Imhann F, Festen EAM, van Bodegraven AA, de Boer NKH, Bouma G, Fidder HH, D'Haens GRAM, Hoentjen F, Hommes DW, de Jong DJ, Löwenberg M, Maljaars PWJ, van der Meulen-de Jong AE, Oldenburg B, Pierik MJ, Ponsioen CY, Stokkers PC, Verspaget HW, Visschedijk MC, van der Woude CJ, Dijkstra G, Weersma RK on behlaf of the Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC). BMJ 2017: in press


2016

Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.

van der Valk ME, Mangen MJ, Severs M, van der Have M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk C, Vermeijden JR, Siersema PD, Leenders M, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis. PLoS One. 2016 Apr 21;11(4):e0142481

Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study.

van der Have M, Oldenburg B, Kaptein AA, Jansen JM, Scheffer RC, van Tuyl BA, van der Meulen-de Jong AE, Pierik M, Siersema PD, van Oijen MG, Fidder HH. J Crohns Colitis. 2016 May;10(5):549-55.

Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.

Severs M, van Erp SJ, van der Valk ME, Mangen MJ, Fidder HH, van der Have M, van Bodegraven AA, de Jong DJ, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, Ponsioen CY, Bolwerk C, Vermeijden JR, Pierik MJ, Siersema PD, Leenders M, van der Meulen-de Jong AE, Dijkstra G, Oldenburg B; Dutch Initiative on Crohn and Colitis. J Crohns Colitis. 2016 Apr;10(4):455-61

Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease.

van den Berg SA, de Boer M, van der Meulen-de Jong AE, Jansen JM, Hoentjen F, Russel MG, Mahmmod N, van Bodegraven AA, van der Woude CJ, Mulder CJ, de Boer NK.
J Crohns Colitis. 2016 Feb;10(2):159-65


2015

Author’s response: The role of risedronate in osteopenia in Crohn’s disease.

van Bodegraven AA, Witt BI, Lips P, Crohn and Bone Study Group of the Dutch Initiative on Crohn and Colitis (ICC).
Gut. 2015 Jan;64(1): 185-6: [Epub 2014 Feb 25] No abstract available.

Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness Perceptions.

van der Have M, Fidder HH, Leenders M, Kaptein AA, van der Valk ME, van Bodegraven AA, Dijkstra G, de Jong DJ, Pierik M, Ponsioen CY, van der Meulen-de Jong AE, van der Woude CJ, van de Meeberg PC, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, Bolwerk CJ, Vermeijden JR, Siersema PD, Oldenburg B.
Inflamm Bowel Dis 2015 Feb; 21(2): 369-77

Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn’s Disease.

Molendijk I, Bonsing BA, Roelofs H, Peeters KC, Wasser MN, Dijkstra G, van der Woude CJ, Duijvestein M, Veenendaal RA, Zwaginga JJ, Verspaget HW, Fibbe WE, van der Meulen-de Jong AE, Hommes DW.
Gastroenterology. 2015 Oct;149(4):918-27

Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.

Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Daryani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JJ, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium, Barrett JC, Franke A, Alizadeh BZ, Parkes M, B K T, Daly MJ, Kubo M, Anderson CA, Weersma RK.
Nat Genet. 2015 Sep;47(9):979-86.

Better survival of renal cell carcinoma in patients with inflammatory bowel disease.

Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Hulsbergen-van de Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis; PALGA Group; IBD/RCC Group.
Oncotarget. 2015 Nov 10;6(35):38336-47

Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy.

van der Valk ME, Mangen MJ, Severs M, van der Have M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk C, Vermeijden JR, Siersema PD, Leenders M, Oldenburg B; COIN study group; Dutch Initiative on Crohn and Colitis.
J Crohns Colitis. 2015 Nov;9(11):1016-23

Predicting Endoscopic Disease Activity in Crohn’s Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index).

Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, Fidder HH, Schwartz MP, Oldenburg B.
Inflamm Bowel Dis. 2015 Oct;21(10):2453-9

Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance.

Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, van der Woude CJ, van Bodegraven AA, Jansen JM, Mahmmod N, Kremer W, Siersema PD, Oldenburg B; Dutch Initiative on Crohn’s and Colitis.
Clin Gastroenterol Hepatol. 2015 Sep;13(9):1656-61


2014

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study.

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Cermeijden JR, Siersema PD, van Oijen MG, Oldenburg B, COIN study group and the Dutch Initiative on Crohn and Colitis.
Gut. 2014 Jan;63(1):72-9

Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future.

van der Have M, Mangen MJ, van der Valk ME, Smeets HM, van Bodegraven A, Dijkstra G, Fidder HH, de Jong DJ, Pierik M, Ponsioen CY, van der Meulen-de Jong AE, van der Woude CJ, van de Meeberg PC, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, Bolwerk CJ, Vermeijden JR, Sierseman PD, Leenders M, Oldenburg B; COIN Study Group; Dutch Initiative on Crohn and Colitis.
Inflamm Bowel Dis. 2014 Apr:20(4):637-45

Risk factors of work diability in patients with inflammatory bowel disease - a Dutch nationwide web-based survey: work disability in inflammatory bowel disease.

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CH, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B; COIN study group; Dutch Initiative on Crohn and Colitis.
J Crohns Colitis. 2014 Jul 1;8(7):590-7

Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.

Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA; Dutch Initiative on Crohn and Colitis.
Gut. 2014 Mar;63(3):451-7

Treatment of bone loss in osteopenic patients with Crohn’s disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplement

van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P; Dutch Initiative on Crohn and Colitis (ICC).
Gut. 2014 Sep;63(9):1424-30

Performance of the Montreal classification for inflammatory bowel diseases.

Spekhorst LM, Visschedijk MC, Alberts R, Festen EA, van der Wouden EJ, Dijkstra G, Weersma RK; Dutch Initiative on Crohn and Colitis.
World J Gastroenterol. 2014 Nov 7;20(41):15374-81

Screening prior to biological therapy in Crohn’s disease: adherence to guidelines and prevalence of infections.  Results from a multicientre retrospective study.

van der Have M, Belderbos TD, Fidder HH, Leenders M, Dijkstra G, Peters CP, Eshuis EJ, Ponsioen CY, Siersema PD, van Oijen MG, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC).
Dig Liver Dis.  2014 Oct;46(10):881-6

Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease.

Derikx LA, Kievit W, Drenth JP, de Jong DJ, Ponsioen CY, Oldenburg B, van der Meulen-de Jong AE, Dijkstra G, Grubben MJ, van Laarhoven CJ, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis
Gastroenterology. 2014 Jan;146(1):119-28


2013

Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease.

de Meij TG, Jharap B, Kneepkens CM, van Bodegraven AA, de Boer NK; The Dutch Initiative on Crohn and Colitis.
Aliment Pharmacol Ther 2013 Jul;38(1):38-43

Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis.

Beaudoin M, Goyette P, Boucher G, Lo KS, Rivas MA, Stevens C, Alikashani A, Ladouceur M, Ellinghaus D, Törkvist L, Goel G, Lagacé C, Annese V, Bitton A, Begun J, Brant SR, Bresso F, Cho JH, Duerr RH, Halfvarson J, McGovern DP, Radford-Smith G, Schreiber S, Schumm PL, Sharma Y, Silverberg MS, Weersma RK; Quebec IBD Genetics Consortium; NIDDK IBD Genetics Consortium; International IBD Genetics Consortium, D'Amato M, Vermeire S, Franke A, Lettre G, Xavier RJ, Daly MJ, Rioux JD,
PLoS Genet. 2013;9(9)

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI).

Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ.
Gut. 2013 Mar 23. [Epub ahead of print]

Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.

Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, Dijkstra G, van der Woude CJ, de Jong DJ, Mulder CJ, van Elburg RM, van Bodegraven AA; for the Dutch Initiative on Crohn and Colitis.
Gut. 2013 Feb 19. [Epub ahead of print]

Adalimumab and Infliximab Are Equally Effective for Crohn’s Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-α Agents.

Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, Ponsioen C, van Tuyl BA, Siersema PD, Fidder HH, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC).
Clin Gastroenterol Hepatol 2013Jul;11(7):826-31.

Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasia.

van Schaik FD, Mooiweer E, van der Have M, Belderbos TD, Ten Kate FJ, Offerhaus GJ, Schipper ME, Dijkstra G, Pierik M, Stokkers PC, Ponsioen C, de Jong DJ, Hommes DW, van Bodegraven AA, Siersema PD, van Oijen MG, Oldenburg B; Dutch Initiative on Crohn Colitis.
Inflamm Bowel Dis. 2013 Feb;19(2):342-9.

Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn’s disease.

Seinen ML, Ponsioen CY, de Boer NK, Oldenburg B, Bouma G, Mulder CJ, van Bodegraven AA.
Clin Gastroenterol Hepatol. 2013 Jun;11(6):667-72.


2012

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: results from the COIN study

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B; on behalf of the COIN study group and the Dutch Initiative on Crohn and Colitis.
Gut. 2012 Nov 7. 

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Nature. 2012 Nov 1;491(7422):119-24.

Risk factors for rectal stump cancer in inflammatory bowel disease

Lutgens MW, van Oijen MG, Vleggaar FP, Siersema PD, Broekman MM, Oldenburg B; Dutch Initiative on Crohn and Colitis. Dis Colon Rectum. 2012 Feb;55(2):191-6. 

Bone cells from patients with quiescent Crohn’s disease show a reduced growth potential and an impeded maturation

Oostlander AE, Bravenboer N, van Essen HW, Klein-Nulend J, Lems WF, Schulten BA, Dijkstra G, van der Woude CJ, van Bodegraven AA, Lips P; Dutch Initiative on Crohn and Colitis. J Cell Biochem. 2012 Jul;113(7):2424-31.


2011

Histomorphometric analysis reveals reduced bone mass and bone formation in patients with quiescent Crohn’s disease

Oostlander AE, Bravenboer N, Sohl E, Holzmann PJ, van der Woude CJ, Dijkstra G, Stokkers PC, Oldenburg B, Netelenbos JC, Hommes DW, van Bodegraven AA, Lips P; Dutch Initiative on Crohn and Colitis (ICC). Gastroenterology. 2011 Jan;140(1):116-23

Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study

Vos AC, Bakkal N, Minnee RC, Casparie MK, de Jong DJ, Dijkstra G, Stokkers P, van Bodegraven AA, Pierik M, van der Woude CJ, Oldenburg B, Hommes DW; for the Initiative on Crohn's and Colitis (ICC). Inflamm Bowel Dis. 2011 Sep;17(9):1837-45

Misclassification of dysplasia in patients with inflammatory bowel disease: Consequences for progression rates to advanced neoplasia

van Schaik FD, Ten Kate FJ, Offerhaus GJ, Schipper ME, Vleggaar FP, van der Woude CJ, Stokkers PC, de Jong DJ, Hommes DW, van Bodegraven AA, Siersema PD, Oldenburg B; on behalf of the Dutch Initiative on Crohn and Colitis (ICC). Inflamm Bowel Dis. 2011 May;17(5):1108-16

Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease

Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, Boucher G, Ripke S, Ellinghaus D, Burtt N, Fennell T, Kirby A, Latiano A, Goyette P, Green T, Halfvarson J, Haritunians T, Korn JM, Kuruvilla F, Lagacé C, Neale B, Lo KS, Schumm P, Törkvist L; National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease Genetics Consortium (NIDDK IBDGC); United Kingdom Inflammatory Bowel Disease Genetics Consortium; International Inflammatory Bowel Disease Genetics Consortium, Dubinsky MC, Brant SR, Silverberg MS, Duerr RH, Altshuler D, Gabriel S, Lettre G, Franke A, D'Amato M, McGovern DP, Cho JH, Rioux JD, Xavier RJ, Daly MJ. Nat Genet. 2011 Oct 9;43(11):1066-73

Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease

Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Verspaget HW, Weersma RK, van der Woude CJ, Stapelbroek JM, Schipper ME, Wijmenga C, van Erpecum KJ, Oldenburg B; Dutch Initiative on Crohn, Colitis (ICC). PLoS One. 2011;6(8):e23745

HNF4 and CDH1 are associated with ulcerative colitis in a Dutch cohort

van Sommeren S, Visschedijk MC, Festen EA, de Jong DJ, Ponsioen CY, Wijmenga C, Weersma RK. Inflamm Bowel Dis. 2011 Aug;17(8):1714-8

Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands

Baars JE, Kuipers EJ, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Oldenburg B, Pierik M, Wahab PJ, van Bodegraven AA, van der Woude CJ; Initiative for Crohn and Colitis. Scand J Gastroenterol. 2011 Mar;46(3):319-25

A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn’s disease and celiac disease

Festen EA, Goyette P, Green T, Boucher G, Beauchamp C, Trynka G, Dubois PC, Lagacé C, Stokkers PC, Hommes DW, Barisani D, Palmieri O, Annese V, van Heel DA, Weersma RK, Daly MJ, Wijmenga C, Rioux JD. PLoS Genet. 2011 Jan 27;7(1):e1001283

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Nat Genet. 2011 Mar;43(3):246-52

Differential association of two PTPN22 coding variants with Crohn’s disease and ulcerative colitis

Diaz-Gallo LM, Espino-Paisán L, Fransen K, Gómez-García M, van Sommeren S, Cardeña C, Rodrigo L, Mendoza JL, Taxonera C, Nieto A, Alcain G, Cueto I, López-Nevot MA, Bottini N, Barclay ML, Crusius JB, van Bodegraven AA, Wijmenga C, Ponsioen CY, Gearry RB, Roberts RL, Weersma RK, Urcelay E, Merriman TR, Alizadeh BZ, Martin J. Inflamm Bowel Dis. 2011 Nov;17(11):2287-94

Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci

Melum E, Franke A, Schramm C, Weismüller TJ, Gotthardt DN, Offner FA, Juran BD, Laerdahl JK, Labi V, Björnsson E, Weersma RK, Henckaerts L, Teufel A, Rust C, Ellinghaus E, Balschun T, Boberg KM, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov JR, Wedemeyer J, Lindkvist B, Wittig M, Porte RJ, Holm K, Gieger C, Wichmann HE, Stokkers P, Ponsioen CY, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U, Villunger A, Schrumpf E, Lazaridis KN, Manns MP, Schreiber S, Karlsen TH. Nat Genet. 2011 Jan;43(1):17-9


2010

Guideline ‘Diagnosis and treatment of inflammatory bowel disease in adults’. I. Diagnosis and treatment

van Bodegraven AA, van Everdingen JJ, Dijkstra G, de Jong DJ, Oldenburg B, Hommes DW; CBO-werkgroep 'IBD bij volwassenen'. Ned Tijdschr Geneeskd. 2010;154:A1899. Dutch

Guideline ‘Diagnosis and treatment of inflammatory bowel disease in adults’. II. Special situations and organisation of medical care

Dijkstra G, Derijks LJ, Houwert GJ, Wolf H, van Bodegraven AA; CBO-werkgroep 'IBD bij volwassenen'. Ned Tijdschr Geneeskd. 2010;154:A1900. Dutch

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn’s disease

van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW; Initiative on Crohn's and Colitis, The Netherlands. Inflamm Bowel Dis. 2010 Oct;16(10):1708-16

Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn’s disease

Fransen K, Visschedijk MC, van Sommeren S, Fu JY, Franke L, Festen EA, Stokkers PC, van Bodegraven AA, Crusius JB, Hommes DW, Zanen P, de Jong DJ, Wijmenga C, van Diemen CC, Weersma RK. Hum Mol Genet. 2010 Sep 1;19(17):3482-8

Genome-wide association identifies multiple ulcerative colitis susceptibility loci

McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, Seielstad M. Nat Genet. 2010 Apr;42(4):332-7

Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk

Festen EA, Stokkers PC, van Diemen CC, van Bodegraven AA, Boezen HM, Crusius BJ, Hommes DW, van der Woude CJ, Balschun T, Verspaget HW, Schreiber S, de Jong DJ, Franke A, Dijkstra G, Wijmenga C, Weersma RK. Am J Gastroenterol. 2010 Feb;105(2):395-402


2009

Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of dectin-1 in inflammatory bowel disease

de Vries HS, Plantinga TS, van Krieken JH, Stienstra R, van Bodegraven AA, Festen EA, Weersma RK, Crusius JB, Linskens RK, Joosten LA, Netea MG, de Jong DJ. PLoS One. 2009 Nov 12;4(11):e7818

Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease

Lutgens MW, Oldenburg B, Siersema PD, van Bodegraven AA, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, van der Woude CJ, Vleggaar FP. Br J Cancer. 2009 Nov 17;101(10):1671-5

More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis

Claessen MM, Lutgens MW, van Buuren HR, Oldenburg B, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Siersema PD, Vleggaar FP. Inflamm Bowel Dis. 2009 Sep;15(9):1331-6

Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis

Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Lian J, Lefèbvre C, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkers PC, Mcgovern D, Palmieri O, Achkar JP, Xavier RJ, Daly MJ, Duerr RH, Wijmenga C, Weersma RK, Rioux JD. Gut. 2009 Jun;58(6):799-804

Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort

Weersma RK, Stokkers PC, van Bodegraven AA, van Hogezand RA, Verspaget HW, de Jong DJ, van der Woude CJ, Oldenburg B, Linskens RK, Festen EA, van der Steege G, Hommes DW, Crusius JB, Wijmenga C, Nolte IM, Dijkstra G; Dutch Initiative on Crohn and Colitis (ICC). Gut. 2009 Mar;58(3):388-95


2008

High frequency of early colorectal cancer in inflammatory bowel disease

Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M. Gut. 2008 Sep;57(9):1246-51


2007


2006

Guidelines for treatment with infliximab for Crohn’s disease

Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G; Dutch Initiative on Crohn and Colitis (ICC). Neth J Med. 2006 Jul-Aug;64(7):219-29


Home / Contact / Disclaimer / Links / © 2022 Initiative on Crohn and Colitis